KNTPF Stock - Kintor Pharmaceutical Limited
Unlock GoAI Insights for KNTPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.00M | N/A | N/A | $34.23M | N/A |
| Gross Profit | $-4,730,000 | $-42,229,000 | $-2,737,238 | $34.23M | $-942,129 |
| Gross Margin | -94.6% | N/A | N/A | 100.0% | N/A |
| Operating Income | $-144,568,000 | $-152,389,649 | $-944,529,000 | $-839,601,000 | $-504,851,000 |
| Net Income | $-155,292,000 | $-1,060,820,000 | $-954,369,000 | $-842,095,000 | $-508,301,000 |
| Net Margin | -3105.8% | N/A | N/A | -2460.0% | N/A |
| EPS | $-0.36 | $-2.47 | $-2.53 | $-2.36 | $-1.64 |
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
KNTPFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 28, 2025 | — | — | — | — |
Q2 2025 | Jun 20, 2025 | — | — | — | — |
Q1 2025 | Mar 26, 2025 | — | — | — | — |
Q3 2024 | Aug 26, 2024 | — | $-0.02 | — | — |
Q2 2024 | Jun 20, 2024 | — | — | — | — |
Q1 2024 | Mar 28, 2024 | — | — | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.28 | — | — |
Q3 2023 | Aug 28, 2023 | — | $-0.07 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.07 | — | — |
Q1 2023 | Mar 30, 2023 | — | — | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.16 | — | — |
Q3 2022 | Aug 29, 2022 | — | $-0.21 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.21 | — | — |
Q1 2022 | Mar 25, 2022 | — | — | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.22 | — | — |
Q3 2021 | Aug 27, 2021 | — | $-0.14 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.14 | — | — |
Q1 2021 | Mar 26, 2021 | — | — | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.14 | — | — |
Q3 2020 | Aug 21, 2020 | — | $-0.10 | — | — |
Latest News
Frequently Asked Questions about KNTPF
What is KNTPF's current stock price?
What is the analyst price target for KNTPF?
What sector is Kintor Pharmaceutical Limited in?
What is KNTPF's market cap?
Does KNTPF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to KNTPF for comparison